Key result
Metabolic syndrome affects ~30% of Indian adults and doubles cardiovascular risk.
Why the study?
Despite historical debate over the definition and value of metabolic syndrome, clinicians continue to rely on it to identify individuals at higher risk of type 2 diabetes and atherosclerotic disease, motivating a synthesis of current evidence alongside newer constructs such as cardiovascular-kidney-metabolic syndrome and the clinical-obesity framework.
Metabolic syndrome remains a practical clinical construct to stratify cardiometabolic risk, especially among South Asians, with management centered on intensive lifestyle changes, incretin-based therapies, and metabolic surgery.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to doubled cardiometabolic risks amid rising prevalence; leaves open optimal integration of incretin therapies in high-risk populations.
Background: Metabolic syndrome (Mets) is a cluster of at least three out of five related medical conditions that together raise the risk of heart disease, stroke, and type 2 diabetes (Cleveland clinic, Ohio). This can lead to central adiposity, dyslipidaemia, increased blood pressure and hyperglycaemia in the same person. The scientists used to argue on its definition and on its value. However, clinicians still rely on MetS to flag individuals who carry a higher risk of type 2 diabetes, atherosclerotic hypertension and other chronic illnesses. Keeping in mind the importance of Mets, we thought of writing this review for a better understanding on this issu This narrative review pulls together current evidence on how MetS is defined, its global and Indian epidemiology, the underlying pathophysiology, the clinical sequelae it produces, and the practical approaches used to manage it. We also analyse the syndrome in the context of newer constructs such as cardiovascular–kidney–metabolic (CKM) syndrome and the emerging clinical-obesity framework. Methods: We examined peer-reviewed papers, consensus statements and pivotal trials, giving priority to systematic reviews, meta-analyses and large population studies published in recent years. Results/Information available: Worldwide prevalence of MetS has nearly doubled since 2000. In India the pooled adult prevalence is near 30 %, higher in cities, particularly among women. Although the main biological effects are insulin resistance, dysfunctional visceral and ectopic fat, and persistent low-grade inflammation, MetS approximately doubles cardiovascular risk and sharply elevates the chances of diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease and some cancers. Intensive lifestyle change remains the foundation of care, while incretin-based drugs and metabolic surgery now deliver meaningful, lasting improvements across several MetS components at once. Conclusions: MetS continues to serve as a practical way to stratify cardiometabolic risk, especially among South Asians who develop metabolic disease at lower levels of adiposity. Priority areas for research and policy include ethnicity-specific thresholds, prevention across the life course, and thoughtful integration with the newer multisystem frameworks.
No takes yet. Share an insight, caveat, or question.
Sadhna Sachdeva¹,Dr. Anand Kar²,Dr. Kiran Billore³ (2026) conducted a review in Metabolic syndrome. Metabolic syndrome management (intensive lifestyle change, incretin-based drugs, metabolic surgery, and herbal management) was evaluated on Prevalence of metabolic syndrome and associated cardiometabolic risk. Metabolic syndrome affects nearly 30% of adults in India, has almost doubled in global prevalence since 2000, and approximately doubles cardiovascular risk.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: